TrialCell reports. Medicine2025

Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific.

Joseph J Sacco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.